ClinicalTrials.gg
Active, not recruitingNCT05967741EASIUpdated Sep 14, 2026

The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation

An interventional study of Erythritol and Aspartame in Platelet Aggregation, Spontaneous and Vascular Thrombosis, sponsored by University of California, Davis. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by University of California, Davis · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 303 studies in Thrombosis with a site in United States — 43 open to participants now, 49 under way, 5 of them phase 3. Thrombosis · United States.

Enrollment
158th of 188
14 · median 67
Started
2023
with 8 others
No phase
50 of 303
5 open now
Primary completion
2026-12
later than 10 of 48 live
Registered
264th of 303
by date

Among the 303 studies in Thrombosis with a site in United States, this one is the 158th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2023, is one of 50 with no phase, reaches primary completion later than 10 of the 48 other live ones, and was the 264th registered.

Thrombosis

956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.

Browse Thrombosis studies →

Open to participants now

43 of the 303 studies in Thrombosis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Thrombosis with a site in United States, or all of them as a file.
02

Study summary

The purpose is to conduct a dietary intervention study in which human participants will consume beverages sweetened with erythritol or aspartame, each for 2 weeks, in a randomized crossover design

Read the detailed description

There is a strong correlation between plasma erythritol concentrations and adverse cardiovascular events in high risk individuals. It has also been demonstrated that consumption of dietary erythritol leads to high levels of plasma erythritol. There is in vitro evidence that erythritol at comparable concentrations promotes platelet activation. However, there is no direct evidence that links human consumption of erythritol with the onset of platelet activation and adhesion leading to inflammation. The investigators seek to fill this evidence gap by conducting a randomized crossover dietary intervention study in which human participants will consume beverages sweetened with erythritol or aspartame, each for two weeks.

03

Conditions studied

  • Platelet Aggregation, Spontaneous
  • Vascular Thrombosis

Browse trials for

Keywords

  • platelet activation
  • vascular inflammation
  • erythritol
  • aspartame
  • dietary intervention
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 27 kg/m2

Exclusion criteria

Exclusion Criteria:

    • History of blood clot, (TIA), stroke, angina, heart attack, or peripheral vascular disease, or current cancer diagnosis.

      • Pregnant or lactating women
      • Current, prior (within 12 months), or anticipated use of medications for treatment of hyperlipidemia, high blood pressure or diabetes, or any medication that in the opinion of the investigators will confound results.
      • Unwilling to forego the use of anti-inflammatory medication during study.
      • Unwilling to forego the use of marijuana during the study.
      • Use of tobacco.
      • Strenuous exerciser (>4 hours/week at a level more vigorous than walking).
      • Surgery or medication for weight loss.
      • Diet exclusions: Food allergies or dietary restrictions that may undermine compliance to dietary protocol, routine ingestion of more than 2 sugar-sweetened beverages or 2 alcoholic beverage/day. Unwillingness to consume artificial or noncaloric sweeteners. Habitual consumption (>10 gram/day) of beverage or foods that contain erythritol. Recent or current weight loss diet.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Erythritol-sweetened beverage

    1-gram erythritol/kg body weight/day, divided into three beverage servings and fruit-flavored with Kool-Aid® unsweetened drink mix.

    Other: Erythritol

  • Placebo comparator
    Aspartame-sweetened beverage

    Control beverages will be made from a noncaloric aspartame-sweetened, fruit-flavored drink mix at the concentration needed to match the sweetness (\~3 mg aspartame/kg/day) and flavoring of the erythritol beverages on a per volume basis.

    Other: Aspartame

Interventions

  • OtherErythritol

    Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)

    Also known as: Noncaloric sugar alcohol

  • OtherAspartame

    Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.

    Also known as: Noncaloric sweetener

06

What researchers measure

Primary outcomes

  1. P-selectin, a platelet surface marker, assessed as median fluorescence intensity

    Change in median fluorescence intensity of P-selectin, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  2. P-selectin, a platelet surface marker, assessed as percentage of P-selectin positive cells

    Change in percentage of P-selectin positive cells, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  3. PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as median fluorescence intensity

    Change in median fluorescence intensity of PAC-1, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  4. PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as percentage of PAC-1 positive cells

    Change in percentage of PAC-1 positive cells, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  5. Annexin V, a platelet surface marker, assessed as median fluorescence intensity

    Change in median fluorescence intensity of annexin V, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  6. Annexin V, a platelet surface marker, assessed as percentage of annexin V positive cells

    Change in percentage of annexin V positive cells, an index of platelet activation, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  7. Platelet reactivity to physiologic agonist, assessed as change in median fluorescence intensity

    The change in median fluorescence intensity induced by physiologic agonists, an index of platelet reactivity, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  8. Platelet aggregation in response to physiologic agonist, assessed as aggregation/min

    The change in aggregation/min induced by physiologic agonists will be measured by light transmission aggregometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  9. Platelet aggregation in response to physiologic agonist, assessed as percent of maximum aggregation

    The change in % maximum aggregation induced by physiologic agonists will be measured by light transmission aggregometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

  10. Platelet-leukocyte interaction, assessed as platelet/leukocyte aggregate size by fluorescence mean intensity

    Change in platelet/leukocyte aggregate size, an index of platelet-leukocyte interaction, will be measured by flow cytometry in whole blood collected from subjects before and after consuming erythritol-sweetened beverage for 2 weeks and compared with change in whole blood collected before and after consuming aspartame-sweetened beverage for 2 weeks

    Time frame: 6 weeks

Secondary outcomes

  1. Plasma concentration of E-Selectin

    Change in plasma E-Selectin in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  2. Plasma concentration of sVCAM1

    Change in plasma sVCAM1 in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  3. Plasma concentration of sICAM1

    Change in plasma sICAM1 in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  4. Plasma concentration of D-dimer

    Change in plasma D-dimer in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  5. Plasma concentration of Platelet factor 4

    Change in plasma platelet factor 4 in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  6. Plasma concentration of Fibrinogen

    Change in plasma fibrinogen in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  7. Plasma concentration of Prothrombin fragment 1+2

    Change in plasma prothrombin fragment 1+2 in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  8. Plasma concentration of Plasmin-antiplasmin complex

    Change in plasma plasmin-antiplasmin complex in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  9. Plasma concentration of Lp(a)

    Change in plasma Lp(a) in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

Other outcomes

  1. Plasma concentration of glucose

    Change in plasma fasting glucose in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  2. Plasma concentration of triglyceride

    Change in plasma fasting triglyceride in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  3. Plasma concentration of cholesterol

    Change in plasma fasting cholesterol in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  4. Plasma concentration of low density lipoprotein cholesterol

    Change in plasma fasting low density lipoprotein cholesterol in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  5. Plasma concentration of high density lipoprotein cholesterol

    Change in plasma fasting high density lipoprotein cholesterol in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  6. Plasma concentration of apolipoprotein B

    Change in plasma fasting apolipoprotein B in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  7. Plasma concentration of apolipoprotein CIII

    Change in plasma fasting apolipoprotein CIII in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

  8. Plasma concentration of uric acid

    Change in plasma fasting uric acid in subjects before and after sustained consumption of erythritol-sweetened beverage compared with change before and after sustained consumption of aspartame-sweetened beverage

    Time frame: 6 weeks

07

Study locations

1 site
  • Ragle Human Nutrition Research Center, University of California, Davis
    Davis, California 95616, United States
08

References and documents

Publications

  • Witkowski M, Nemet I, Alamri H, Wilcox J, Gupta N, Nimer N, Haghikia A, Li XS, Wu Y, Saha PP, Demuth I, Konig M, Steinhagen-Thiessen E, Cajka T, Fiehn O, Landmesser U, Tang WHW, Hazen SL. The artificial sweetener erythritol and cardiovascular event risk. Nat Med. 2023 Mar;29(3):710-718. doi: 10.1038/s41591-023-02223-9. Epub 2023 Feb 27. PubMed 36849732 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 109 non-industry interventional studies with no phase under Thrombosis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 41 months is above that.

Counting every sponsor, half of 116 studies reached it within 24 months; a quarter within 9 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Aug 1, 2023
StartActual
Jul 20, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967741
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jul 20, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion